anti-EpCAM-maytansinoid immunoconjugates (ImmunoGen)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-EpCAM-maytansinoid immunoconjugates (ImmunoGen)

Drug Alias NameEpCAM-targeted maytansinoid immunotoxins (ImmunoGen)anti-EpCAM-PEG4-DM1chB38.1-IGN14anti-CD33-IGN-14Anti-EpCAM-IGN-14 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsEpithelial cell adhesion molecule inhibitors

TargetsMyeloid cell surface antigen CD33Epithelial cell adhesion molecule

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A